GENMAB A/S (GE9.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:GE9 - DK0010272202 - Common Stock
GE9.DE Key Statistics, Chart & Performance
The current stock price of GE9.DE is 269.6 EUR.
GE9.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 68.26 | 44.55B | ||
| 1AE.DE | ARGENX SE | 70.98 | 46.32B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 19.20B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.11B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.08B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.75B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.75B | ||
| 1CVAC.MI | CUREVAC NV | 5.04 | 987.60M | ||
| 5CV.DE | CUREVAC NV | 7.27 | 949.32M | ||
| NANO.PA | NANOBIOTIX | N/A | 932.49M | ||
| IVA.PA | INVENTIVA SA | N/A | 710.59M | ||
| PHIL.MI | PHILOGEN SPA | 20.61 | 687.14M |
Related stock screener links
About GE9.DE
Company Profile
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Company Info
GENMAB A/S
Carl Jacobsens Vej 30
Valby DK
Employees: 2682
Phone: 4570202728
GENMAB A/S / GE9.DE FAQ
Can you describe the business of GENMAB A/S?
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
What is the stock price of GENMAB A/S today?
The current stock price of GE9.DE is 269.6 EUR. The price increased by 0.26% in the last trading session.
Does GENMAB A/S pay dividends?
GE9.DE does not pay a dividend.
How is the ChartMill rating for GENMAB A/S?
GE9.DE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What sector and industry does GENMAB A/S belong to?
GENMAB A/S (GE9.DE) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for GE9 stock?
GENMAB A/S (GE9.DE) currently has 2682 employees.
What is the market capitalization of GE9 stock?
GENMAB A/S (GE9.DE) has a market capitalization of 166.07B EUR. This makes GE9.DE a Large Cap stock.
GE9.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to GE9.DE.
GE9.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to GE9.DE. Both the health and profitability get an excellent rating, making GE9.DE a very profitable company, without any liquidiy or solvency issues.
GE9.DE Financial Highlights
Over the last trailing twelve months GE9.DE reported a non-GAAP Earnings per Share(EPS) of 20. The EPS decreased by -34.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.35% | ||
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| Debt/Equity | 0.02 |
GE9.DE Forecast & Estimates
27 analysts have analysed GE9.DE and the average price target is 290.5 EUR. This implies a price increase of 7.75% is expected in the next year compared to the current price of 269.6.
For the next year, analysts expect an EPS growth of -48.21% and a revenue growth 22.77% for GE9.DE